HOME > Achievement

Achievement

Cervical Cancer(Vulva Cancer) Committee

  1. Feasibility and Acute Toxicity of Concurrent Chemoradiotherapy (CCRT) With High-Dose Rate Intracavitary Brachytherapy (HDR-ICBT) and 40-mg/m2 Weekly Cisplatin for Japanese Patients With Cervical Cancer: Results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
    Int J Gynecol Cancer. 2012; 22: 1420-26.
    link
  2. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
    Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, Kubushiro K, Kokawa K, Hiura M, Mizutani K, Yamamoto K, Takizawa K.
    Oncol Rep. 2012; 28: 487-93.
    link
  3. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule.
    Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of the Japanese Gynecologic Oncology Group (JGOG).
    Gynecol Oncol. 2012; 126: 211-6.
    link
  4. Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; and Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group.
    Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.
    Int J Clin Oncol. 2011; 16 : 379-86.
    link
  5. Yamamoto K, Kokawa K, Umesaki N, Nishimura R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H, Takizawa K.
    Phase I study of combination chemotherapy with irinotecan hydrochloride and nedaplatin for cervical squamous cell carcinoma: Japanese gynecologic oncology group study.
    Oncol Rep. 2009 Apr;21(4):1005-9.
    link
  6. Kokawa,K., Umesaki,N., Yamamoto,K., Takizawa, K., Konishi, I., Hasegawa,K.,;
    Phase I study of irinotecan combined with mitomycin- C and 5-fluorouracil for gynecological malignancies;
    The JGOG Study. Anticancer Research 28;2933-2939 (2008)
    link
  7. Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R, Okuda H, Takahashi T, Origasa H, Sugimori H. Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. Int J Oncol. 2004 May;24(5):1175-9
    link
  8. Umesaki N, Fujii T, Nishimura R, Tanaka T, Nishida M, Fushiki H, Takizawa K, Yamamoto K, Hasegawa K, Izumi R; Japan Gynecologic Oncology Group. Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study. Gynecol Oncol. 2004 Oct;95(1):127-32.
    link
  9. Umesaki N, Izumi R, Fushiki H, Hasegawa K, Kono I, Nishida M, Noguchi H, Okuda H, Sugimori H, Takizawa K, Udagawa Y, Yamamoto K, Tanaka T, Noda K. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease. Gynecol Oncol.1999 Oct;75(1):142-4.
    link

Uterine Cancer Committee

  1. H. Nomura, D. Aoki, F. Takahashi, N. Katsumata, Y. Watanabe, I. Konishi, T. Jobo, M. Hatae, M. Hiura, N. Yaegashi,
    Japanese Gynecologic Oncology Group
    Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).
    Annals of Oncology 2011: 22: 636-42
    link
  2. Watanabe Y, Kitagawa R, Aoki D, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N;
    Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
    Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group(JGOG2044s).
    Gynecol Oncol. 2009 Dec;115(3):456-9.
    link
  3. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R;
    Japanese Gynecologic Oncology Group.
    Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Gynecol Oncol. 2008 Jan;108(1):226-33.
    link
  4. Watanabe Y, Aoki D, Kitagawa R, Takeuchi S, Sagae S, Sakuragi N, Yaegashi N;
    Disease Committee of Uterine Endometrial Cancer, Japanese Gynecologic Oncology Group.
    Status of surgical treatment procedures for endometrial cancer in Japan: results of a Japanese Gynecologic Oncology Group survey.(JGOG2045s)
    Gynecol Oncol. 2007 May;105(2):325-8.
    link

Ovarian Cancer Committee

  1. Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K.
    Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    Int J Clin Oncol. 2011 Nov 30.
    link
  2. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K; Japanese Gynecologic Oncology Group.
    Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
    Int J Gynecol Cancer. 2010; 20: 240-7.
    link
  3. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K; Japanese Gynecologic Oncology Group.
    Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
    Lancet. 2009 Oct 17;374(9698):1331-8.
    link
  4. Hatae M, Onishi Y, Noda K, Yakushiji M, Ozaki K, Ochiai K, Kuzuya K, Takahashi T, Tateno M, Yoshikawa H, Nishida T.
    RANDOMIZED TRIAL ON ADJUVANT IV CHEMOTHERAPY CDDP + CPA VERSUS PO CHEMOTHERAPY CPA FOR STAGE IA OVARIAN CANCER BY THE JAPANESE GYNECOLOGIC ONCOLOGY AND CHEMOTHERAPY STUDY GROUP (Meeting abstract). 1998 ASCO Annual Meeting Abstract No: 1412
    link
  • Organization Chart
  • Board of Directors
  • Crinical Trial
  • Achievement
  • JGOG COI Policy
  • Newsletter
  • Related Links

JGOG Administration Office
4F, Komatsu Building, 6-22, Kagurazaka, Shinjuku-ku,
Tokyo, 162-0825,
Japan
E-mail : info-e@jgog.gr.jp

top